Clinical Trial Update: Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver [Phase 4]

View source ↗

Summary

Clinical trial update reporting the termination of a Phase 4 study assessing rosiglitazone added to standard therapy for hepatitis C genotype 1 with fatty liver…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver
• Hepatitis C

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Beth Israel Medical Center | Conditions: Chronic Hepatitis C Infection, Fatty Liver | Phase 4 | Status: TERMINATED